A "Real-World", Randomized, Open-Label, Study on the Efficacy, Safety, and Tolerability of Tecarfarin (ATI-5923) a Novel Vitamin K Antagonist, Versus Warfarin in Subjects Requiring Chronic Anticoagulation
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Jan 2018
Price : $35 *
At a glance
- Drugs Tecarfarin (Primary) ; Warfarin
- Indications Thromboembolism; Thrombosis
- Focus Registrational; Therapeutic Use
- Acronyms TACT
- Sponsors Armetheon; Espero BioPharma; Espero Pharmaceuticals
- 23 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Jul 2019.
- 23 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 30 Mar 2019.
- 23 Jan 2018 Planned initiation date changed from 1 Dec 2016 to 1 Jun 2018.